Steven Boyd’s Armistice Capital: Championing Innovation in Rare Disease and Women’s Health Investments
The landscape of healthcare investments is evolving, with a growing focus on addressing unmet medical needs, particularly in rare diseases and women's health. At the forefront of this shift is Armistice Capital, a global value-oriented and event-driven hedge fund led by Steven Boyd. This fund has demonstrated a keen interest in supporting companies that are pushing the boundaries of medical research and technology. While the overall biotech...